While we previously discussed how rare disease research has dramatically increased in both academic and industrial research, clinical trials of potential rare disease…

We previously discussed how there are software methods to screen for potential drug leads and researchers have been able to increase their drug…

Previously, we discussed in part 1 of this series the growing significance of computational methods in drug discovery. Traditional drug discovery typically uses…

Traditional drug discovery is expensive, inefficient, and has huge barriers to entry. Big pharmaceutical companies continue to struggle to cope with tight margins…

This is the third in a three-part series by Dr. Heather Buschman on Big Data in the pharmaceutical and biotechnology industries. Check out…